Travere Therapeutics gains FDA approval for sparsentan in FSGS

Filspari’s dual action targets endothelin A and angiotensin II receptors, reducing stress, inflammation and scarring in the kidneys linked to FSGS. Credit: sasirin pamai/Shutterstock.com.



  • Travere FDA approval